Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1751-1755

  Niki, Yoshihito ^a   Itokawa, Kenichi ^b   Okazaki, Osamu ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SITAFLOXACIN; THEOPHYLLINE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031862824     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1751     Document Type: Article

References (32)

1. Aoki, H., Y. Ohshima, M. Tanaka, O. Okazaki, and H. Hakusui. 1994. High-performance liquid chromatographic determination of the new quinolone antibacterial agent DU-6859a in human serum and urine using solid-phase extraction with photolysis-fluorescence detection. J. Chromatogr. 660: 365-374.
2. Campbell, M. E., D. M. Grant, T. Inaba, and W. Kalow. 1987. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes. Drug Metab. Dispos. 15:237-249.
3. Edward, D. J., S. K. Bowles, C. K. Svensson, and M. J. Rybak. 1988. Inhibition of drug metabolism by quinolone antibiotics. Clin. Pharmacokinet. 15:194-204.
4. Fuhr, U., E.-M. Anders, G. Mahr, F. Sörgel, and A. H. Staib. 1992. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob. Agents Chemother. 36:942-948.
5. Gaspari, F., and M. Bonati. 1990. Interspecies metabolism and pharmacokinetic scaling of theophylline disposition. Drug Metab. Rev. 22:179-207.
6. Grygiel, J. J., and D. J. Birkett. 1981. Cigarette smoking and theophylline clearance and metabolism. Clin. Pharmacol. Ther. 30:491-496.
7. Grygiel, J. J., L. M. H. Wing, J. Farkas, and D. J. Birkett. 1979. Effect of allopurinol on theophylline metabolism and clearance. Clin. Pharmacol. Ther. 26:660-667.
8. Gu, L., F. J. Gonzalez, W. Kalow, and B. K. Tang. 1992. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77.
9. Gundert-Remy, U., R. Hildebrandt, N. Hengen, and E. Weber. 1983. Nonlinear elimination processes of theophylline. Eur. J. Clin. Pharmacol. 24:71-78.
10. Kokufu, T., N. Ihara, N. Sugioka, H. Koyama, T. Ohta, S. Mori, and K. Nakajima. 1995. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur. J. Clin. Pharmacol. 48:391-395.
11. Konishi, H., and A. Yamaji. 1994. Measurement of theophylline metabolites produced by reaction with hepatic microsome by high performance liquid chromatography following solid phase extraction. Biomed. Chromatogr. 8: 189-192.
12. Loi, C. M., B. M. Parker, B. J. Cusack, and R. E. Vestal. 1993. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br. J. Clin. Pharmacol. 36:195-200.
13. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-276.
14. McManus, M. E., J. O. Miners, D. Gregor, I. Stupans, and D. J. Birkett. Theophylline metabolism by human, rabbit and rat liver microsomes and by purified form of cytochrome P450. J. Pharm. Pharmacol. 40:388-391.
15. Mizuki, Y., M. Kamaura, T. Yamaguchi, Y. Sekine, and H. Hashimoto. 1989. Interaction of enoxacin with theophylline in rat. Arzneim.-Forsch. 39:593-597.
16. Nakashima, M., T. Uematsu, K. Kosuge, K. Umemura, H. Hakusui, and M. Tanaka. 1995. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother. 39:170-174.
17. Niki, Y., M. Nakajima, K. Hashiguchi, M. Nakabayashi, S. Tamada, N. Okimoto, and R. Soejima. 1995. Effect of grepafloxacin on serum concentration of theophylline. Chemotherapy 43(Suppl. 1):184-189.
18. Ogura, Y., T. Hasegawa, Y. Yokochi, S. Yamada, S. Kitazawa, and K. Takagi. Clinical application of substrate-labeled fluorescent immunoassay with antiserum produced using 9-theophylline-BSA immunogen. Jpn. J. Hosp. Pharmacol. 9:260-266.
19. Okazaki, O., H. Aoki, T. Kurata, and H. Hakusui. 1991. Metabolic disposition of DU-6859 in rats, abstr. 1508, p. 350. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Okazaki, O., T. Kurata, and H. Tachizawa. 1988. Effect of new quinolones on drug-metabolizing enzyme system of rat hepatic microsomes. Chemotherapy 34:149-154.
21. Omura, T., and R. Sato. 1964. The carbon monooxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378.
22. Riem Ha, H., J. Chen, A. U. Freiburghaus, and F. Follath. 1995. Metabolism of theophylline by cDNA expressed human cytochromes P-450. Br. J. Clin. Pharmacol. 39:321-326.
23. Sarkar, M. A., C. Hunt, P. S. Guzelian, and T. Karnes. 1992. Characterization of human liver cytochrome P-450 involved in theophylline metabolism. Drug Metab. Dispos. 20:31-37.
24. Sato, K., K. Hoshino, M. Tanaka, I. Hayakawa, and Y. Osada. 1992. Antimicrobial activity of DU-6859a, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 36:1491-1498.
25. Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. 1994. Inter individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423.
26. Shimada, T., M. Iwasaki, M. V. Martin, and F. P. Guengerich. 1989. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK 1002. Cancer Res. 49:3218-3228.
27. Tang-Liu, D. D., R. L. Wing, and S. Riegelman. 1982. Nonlinear theophylline elimination. Clin. Pharmacol. Ther. 31:358-369.
28. Tjia, J. F., J. Colbert, and D. J. Back. 1996. Theophylline metabolism in human liver microsomes: inhibition studies. J. Pharmacol. Exp. Ther. 276: 912-917.
29. Upton, R. A. 1991. Pharmacokinetic interactions between theophylline and other medication. Clin. Pharmacokinet. 20:66-80.
30. Wijnands, W. J. A., C. L. A. Herwaarden, and T. B. van Vree. 1984. Enoxacin raises plasma theophylline concentrations. Lancet ii:108-109.
31. Wijnands, W. J. A., T. B. Vree, and C. L. A. van Herwaarden. 1985. Enoxacin decreases the clearance of theophylline in man. Br. J. Clin. Pharmacol. 20: 583-588.
32. Wrighton, S. A., and J. C. Stevens. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22:1-21.